Complete Filing Data
Taysha Gene Therapies, Inc. reported Stockholders Equity of $246.94 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Taysha Gene Therapies, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income * | -$109.0M | -$89.3M | -$111.6M | -$166.0M | -$174.5M | -$60.0M |
| Operating Income Loss | -$110.5M | -$91.5M | -$72.4M | -$162.4M | -$173.3M | -$43.0M |
| Operating Expenses | $120.3M | $99.8M | $87.9M | $164.9M | $173.3M | $43.0M |
| General And Administrative Expense | $33.9M | $29.0M | $30.0M | $37.4M | $41.3M | $11.1M |
| Research And Development Expense | $86.4M | $66.0M | $56.8M | $91.2M | $131.9M | $31.9M |
| Nonoperating Income Expense | $1.5M | $2.2M | -$39.1M | -$3.6M | -$1.3M | -$17.0M |
| Interest Expense | $5.0M | $3.8M | $1.4M | $28.0K | ||
| Interest Income Expense Nonoperating Net | $3.6M | $249.0K | $172.0K | $49.0K | ||
| Other Nonoperating Income Expense | -$291.0K | -$110.0K | -$47.0K | -$18.0K | ||
| Revenues | $9.8M | $8.3M | $15.5M | $2.5M | ||
| Deferred Revenue Current | $9.8M | $18.1M | $33.6M | |||
| Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | -$105.2M | -$93.3M | -$111.6M | |||
| Research And Development In Process | $1.3M | $9.8M | $9.0M | |||
| Interest Expense Nonoperating | $63.0K | $102.0K | $5.0M | |||
| Impairment Of Long Lived Assets Held For Use | $0.00 | $4.8M | $1.1M | $36.4M | $0.00 | |
| Research And Development License Not Yet Paid | $3.0M | $3.5M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$32.7M | -$26.9M | -$21.5M | -$25.5M | -$20.9M | -$24.1M | -$117.1M | -$24.6M | -$17.6M | -$26.5M | -$34.1M | -$50.3M | -$51.2M | -$40.9M | -$32.0M | -$15.0M | -$21.2M | -$5.4M | -$1.1M | -$31.0K |
| Operating Income Loss | -$34.0M | -$26.8M | -$21.4M | -$25.9M | -$21.3M | -$24.3M | -$16.3M | -$23.4M | -$16.6M | -$25.5M | -$33.4M | -$49.7M | -$50.7M | -$40.8M | -$32.1M | -$15.0M | -$4.0M | -$5.6M | -$1.1M | -$31.0K |
| Operating Expenses | $34.0M | $28.7M | $23.7M | $27.7M | $22.4M | $27.7M | $21.0M | $25.8M | $21.3M | $25.5M | $33.4M | $49.7M | $50.7M | $40.8M | $32.1M | $15.0M | $4.0M | $5.6M | $1.1M | $31.0K |
| General And Administrative Expense | $8.3M | $8.6M | $8.2M | $7.9M | $7.3M | $7.1M | $8.6M | $6.0M | $8.8M | $8.7M | $9.9M | $11.5M | $11.2M | $10.1M | $8.2M | $4.0M | $948.0K | $70.0K | $128.0K | $31.0K |
| Research And Development Expense | $25.7M | $20.1M | $15.6M | $14.9M | $15.1M | $20.7M | $11.8M | $19.8M | $12.5M | $16.8M | $23.5M | $38.2M | $39.5M | $30.6M | $23.9M | $11.1M | $3.1M | $5.5M | $987.0K | |
| Nonoperating Income Expense | $1.3M | -$129.0K | -$108.0K | $374.0K | $371.0K | $269.0K | -$100.8M | -$1.2M | -$1.1M | -$1.1M | -$719.0K | -$666.0K | -$506.0K | -$154.0K | $66.0K | -$1.0K | -$17.2M | $153.0K | ||
| Interest Expense | $27.0K | $29.0K | $1.5M | $1.4M | $1.4M | $1.1M | $743.0K | $672.0K | $543.0K | $194.0K | $1.0K | $27.0K | ||||||||
| Interest Income Expense Nonoperating Net | $1.4M | $1.7M | $1.1M | $223.0K | $319.0K | $9.0K | $27.0K | $14.0K | $37.0K | $40.0K | $66.0K | |||||||||
| Other Nonoperating Income Expense | -$37.0K | -$237.0K | $13.0K | -$81.0K | $42.0K | -$5.0K | -$19.0K | $3.0K | -$8.0K | -$1.0K | -$3.0K | |||||||||
| Revenues | $0.00 | $2.0M | $2.3M | $1.8M | $1.1M | $3.4M | $4.7M | $2.4M | $4.7M | |||||||||||
| Deferred Revenue Current | $5.5M | $5.5M | $7.5M | $11.8M | $13.6M | $14.7M | $18.8M | $20.2M | $28.9M | |||||||||||
| Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | -$33.2M | -$25.3M | -$19.8M | -$30.3M | -$18.3M | -$24.3M | -$117.1M | -$24.6M | -$17.6M | |||||||||||
| Research And Development In Process | $1.3M | $5.5M | $3.0M | $980.0K | $0.00 | |||||||||||||||
| Interest Expense Nonoperating | $15.0K | $17.0K | $19.0K | $24.0K | $27.0K | $29.0K | $1.5M | |||||||||||||
| Impairment Of Long Lived Assets Held For Use | $0.00 | $4.8M | $616.0K | |||||||||||||||||
| Research And Development License Not Yet Paid | $1.3M | $5.5M | $3.0M | $0.00 |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Stockholders Equity | $246.9M | $71.5M | $74.9M | $949.0K | $95.4M | $251.3M | -$135.0K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $322.5M | $141.6M | $146.5M | $90.5M | $151.7M | $251.3M | $0.00 |
| Cash And Cash Equivalents At Carrying Value | $319.8M | $139.0M | $143.9M | $87.9M | $149.1M | $251.3M | |
| Retained Earnings Accumulated Deficit | -$711.3M | -$602.3M | -$513.0M | -$401.4M | -$235.6M | -$61.1M | -$1.1M |
| Liabilities Current | $26.6M | $26.2M | $36.8M | $62.8M | $51.7M | $7.1M | $150.0K |
| Liabilities And Stockholders Equity | $343.3M | $160.4M | $172.7M | $126.3M | $214.0M | $258.9M | $15.0K |
| Liabilities | $96.4M | $88.8M | $97.8M | $125.3M | $118.6M | $7.6M | $150.0K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $180.9M | -$4.9M | $56.0M | -$61.2M | -$99.5M | $251.3M | |
| Assets Current | $324.6M | $142.1M | $149.9M | $96.4M | $159.6M | $257.9M | $15.0K |
| Assets | $343.3M | $160.4M | $172.7M | $126.3M | $214.0M | $258.9M | $15.0K |
| Property Plant And Equipment Net | $6.7M | $7.5M | $10.8M | $15.0M | $50.6M | $287.0K | |
| Accrued Liabilities And Other Liabilities | $20.3M | $12.9M | $12.3M | $18.3M | $30.0M | $5.1M | $150.0K |
| Accounts Payable Current | $6.3M | $3.6M | $6.4M | $10.9M | $21.8M | $2.0M | |
| Prepaid Expense And Other Assets Current | $4.4M | $2.6M | $3.5M | $8.5M | $10.5M | $6.6M | |
| Other Liabilities Noncurrent | $1.6M | $1.3M | $1.6M | $4.1M | $3.7M | $450.0K | |
| Restricted Cash | $2.8M | $2.6M | $2.6M | $2.6M | $2.6M | ||
| Long Term Debt Noncurrent | $50.1M | $43.9M | $40.5M | $38.0M | $37.2M | ||
| Property And Equipment In Accounts Payable And Accrued Expenses | $41.0K | $346.0K | $4.0M | $8.3M | $214.0K | ||
| Other Assets Noncurrent | $183.0K | $217.0K | $304.0K | $1.3M | $1.1M | ||
| Common Stock Value | $3.0K | $2.0K | $2.0K | $1.0K | |||
| Operating Lease Right Of Use Asset Amortization Expense | $1.4M | $1.2M | $1.2M | $1.3M | |||
| Operating Lease Right Of Use Asset | $9.4M | $8.4M | $9.6M | $10.9M | |||
| Operating Lease Liability Noncurrent | $18.2M | $17.4M | $19.0M | $20.4M | |||
| Change In Fair Value Of Warrant Liability | $1.2M | -$16.0K | $34.7M | ||||
| Restricted Cash Noncurrent | $2.3M | $2.2M | $2.2M | $2.6M | |||
| Restricted Cash Current | $449.0K | $449.0K | $449.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $219.0M | $248.7M | $55.1M | $88.8M | $108.9M | $53.8M | -$49.1M | -$37.1M | -$14.9M | $10.7M | $32.5M | $50.7M | $140.4M | $186.5M | $222.9M | $267.6M | -$26.8M | -$5.6M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $299.9M | $299.9M | $119.2M | $160.3M | $175.3M | $126.6M | $166.9M | $47.7M | $66.1M | $36.9M | $68.9M | $99.3M | $191.4M | $197.4M | $228.7M | $278.6M | $11.2M | $16.3M | $0.00 | |
| Cash And Cash Equivalents At Carrying Value | $297.3M | $312.8M | $116.6M | $157.7M | $172.7M | $124.0M | $164.3M | $45.1M | $63.4M | $34.3M | $66.2M | $96.6M | $188.8M | $197.4M | $228.7M | $278.6M | ||||
| Retained Earnings Accumulated Deficit | -$683.4M | -$650.7M | -$623.8M | -$583.5M | -$558.0M | -$537.1M | -$560.7M | -$443.7M | -$419.1M | -$345.9M | -$319.6M | -$285.8M | -$185.3M | -$134.1M | -$93.2M | -$42.8M | ||||
| Liabilities Current | $28.6M | $25.3M | $22.6M | $29.3M | $34.2M | $38.6M | $180.5M | $50.6M | $54.5M | $33.1M | $43.0M | $48.6M | $43.2M | $28.4M | $19.0M | $11.6M | ||||
| Liabilities And Stockholders Equity | $316.6M | $333.3M | $138.4M | $180.2M | $200.4M | $153.0M | $195.8M | $81.5M | $101.6M | $111.5M | $142.3M | $166.0M | $241.0M | $241.9M | $242.8M | $279.3M | ||||
| Liabilities | $97.6M | $84.6M | $83.3M | $91.4M | $91.5M | $99.2M | $244.9M | $118.7M | $116.5M | $100.3M | $109.6M | $115.3M | $100.6M | $55.4M | $20.0M | $11.6M | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$22.4M | -$20.0M | -$24.5M | -$52.5M | -$22.6M | $16.3M | $0.00 | $0.00 | ||||||||||||
| Assets Current | $300.0M | $316.3M | $120.7M | $161.6M | $178.5M | $130.6M | $171.8M | $54.1M | $72.4M | $43.0M | $76.8M | $106.9M | $197.2M | $207.3M | $239.6M | $279.2M | ||||
| Assets | $316.6M | $333.3M | $138.4M | $180.2M | $200.4M | $153.0M | $195.8M | $81.5M | $101.6M | $111.5M | $142.3M | $166.0M | $241.0M | $241.9M | $242.8M | $279.3M | ||||
| Property Plant And Equipment Net | $6.8M | $7.0M | $7.2M | $7.6M | $10.5M | $10.7M | $11.2M | $14.1M | $14.6M | $64.0M | $61.0M | $55.1M | $40.6M | $33.9M | $2.5M | $28.0K | ||||
| Accrued Liabilities And Other Liabilities | $17.7M | $12.2M | $10.8M | $12.6M | $11.9M | $13.6M | $13.6M | $19.6M | $16.6M | $17.9M | $19.0M | $26.6M | $21.2M | $22.0M | $14.9M | |||||
| Accounts Payable Current | $5.4M | $7.7M | $4.3M | $4.9M | $8.7M | $10.4M | $7.5M | $10.8M | $9.0M | $15.3M | $24.0M | $22.0M | $22.1M | $6.4M | $4.1M | $8.8M | ||||
| Prepaid Expense And Other Assets Current | $2.2M | $3.1M | $3.7M | $3.4M | $3.3M | $4.2M | $5.5M | $9.0M | $8.9M | $8.7M | $10.6M | $10.3M | $8.4M | $9.9M | $10.8M | |||||
| Other Liabilities Noncurrent | $1.6M | $1.4M | $1.2M | $1.4M | $1.4M | $1.5M | $3.8M | $3.9M | $4.0M | $3.9M | $3.5M | $3.5M | $3.0M | $765.0K | $999.0K | |||||
| Restricted Cash | $2.6M | $2.6M | $2.6M | $2.6M | $2.6M | $2.6M | $2.6M | $2.6M | $2.6M | $2.6M | $2.6M | $2.6M | $2.6M | |||||||
| Long Term Debt Noncurrent | $50.9M | $41.1M | $42.5M | $43.0M | $37.8M | $40.5M | $38.5M | $38.4M | $38.2M | $37.8M | $37.6M | $37.4M | $27.8M | |||||||
| Property And Equipment In Accounts Payable And Accrued Expenses | $52.0K | $112.0K | $4.5M | $1.1M | $0.00 | $0.00 | ||||||||||||||
| Other Assets Noncurrent | $184.0K | $186.0K | $188.0K | $220.0K | $288.0K | $304.0K | $304.0K | $304.0K | $1.3M | $1.2M | $1.2M | $673.0K | ||||||||
| Common Stock Value | $3.0K | $3.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $1.0K | $1.0K | $1.0K | $1.0K | |||||||||
| Operating Lease Right Of Use Asset Amortization Expense | $339.0K | $325.0K | $300.0K | $309.0K | ||||||||||||||||
| Operating Lease Right Of Use Asset | $7.5M | $7.8M | $8.1M | $8.7M | $9.0M | $9.3M | $9.9M | $10.3M | $10.6M | |||||||||||
| Operating Lease Liability Noncurrent | $16.5M | $16.8M | $17.1M | $17.8M | $18.1M | $18.5M | $19.1M | $19.5M | $19.9M | |||||||||||
| Change In Fair Value Of Warrant Liability | $292.0K | $273.0K | -$102.0K | -$75.0K | -$195.0K | $337.0K | $100.5M | |||||||||||||
| Restricted Cash Noncurrent | $2.2M | $2.2M | $2.2M | $2.2M | $2.2M | $2.2M | ||||||||||||||
| Restricted Cash Current | $449.0K | $449.0K | $449.0K | $449.0K | $449.0K | $449.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$93.1M | -$81.2M | -$73.0M | -$88.4M | -$117.0M | -$30.7M |
| Net Cash Provided By Used In Investing Activities | -$604.0K | -$363.0K | -$7.4M | -$24.9M | -$21.6M | -$9.1M |
| Increase Decrease In Accounts Payable | -$153.0K | -$2.9M | -$2.3M | -$7.8M | $14.5M | $2.0M |
| Share Based Compensation | $13.3M | $13.1M | $7.9M | $18.0M | $18.2M | $3.4M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $1.7M | -$207.0K | -$6.0M | -$2.1M | $3.4M | $6.6M |
| Increase Decrease In Accrued Expense And Other Liabilities | $6.3M | -$1.4M | -$6.3M | -$9.3M | $17.5M | $4.5M |
| Payments To Acquire Property Plant And Equipment | $738.0K | $374.0K | $3.9M | $20.6M | $15.3M | $82.0K |
| Net Cash Provided By Used In Financing Activities | $274.6M | $76.7M | $136.4M | $52.1M | $39.1M | $291.1M |
| Proceeds From Payments For Other Financing Activities | -$337.0K | -$167.0K | -$229.0K | -$1.0M | -$514.0K | |
| Payments To Acquire In Process Research And Development | $3.5M | $4.3M | $6.3M | $9.0M | ||
| Proceeds From Stock Plans | $159.0K | $89.0K | $68.0K | $253.0K | ||
| Increase Decrease In Contract With Customer Liability | -$9.8M | -$8.3M | -$15.5M | $33.6M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 | Q4 2019 | Q3 2019 |
|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$22.0M | -$19.8M | -$20.2M | -$40.9M | -$22.0M | -$1.7M | $0.00 | $0.00 |
| Net Cash Provided By Used In Investing Activities | -$371.0K | -$140.0K | -$3.9M | -$11.4M | -$534.0K | $0.00 | $0.00 | $0.00 |
| Increase Decrease In Accounts Payable | $923.0K | $4.0M | $359.0K | $2.5M | $1.9M | $0.00 | $0.00 | $0.00 |
| Share Based Compensation | $3.3M | $3.2M | $1.7M | $5.3M | $3.6M | $0.00 | $0.00 | $0.00 |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $1.1M | $693.0K | $400.0K | -$271.0K | $4.2M | $0.00 | $0.00 | |
| Increase Decrease In Accrued Expense And Other Liabilities | -$2.1M | $422.0K | -$250.0K | -$779.0K | $3.2M | $907.0K | $135.0K | |
| Payments To Acquire Property Plant And Equipment | $140.0K | $3.9M | $8.4M | $534.0K | $0.00 | $0.00 | $0.00 | |
| Net Cash Provided By Used In Financing Activities | -$52.0K | -$22.0K | -$370.0K | -$107.0K | $18.0M | $0.00 | $0.00 | |
| Proceeds From Payments For Other Financing Activities | -$80.0K | -$30.0K | -$33.0K | -$233.0K | ||||
| Payments To Acquire In Process Research And Development | $378.0K | $140.0K | $3.0M | $0.00 | $0.00 | |||
| Proceeds From Stock Plans | $75.0K | $26.0K | $50.0K | $277.0K | ||||
| Increase Decrease In Contract With Customer Liability | -$2.3M | -$3.4M | -$4.7M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.34 | -$0.36 | -$0.96 | -$3.78 | -$4.64 | -$3.40 | |
| Common Stock Shares Authorized | 700.0M | 400.0M | 400.0M | 200.0M | 200.0M | 200.0M | 10.9M |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 0.00 |
| Weighted Average Number Of Shares Outstanding Basic | 319.7M | 250.1M | 116.1M | 44.0M | 37.7M | ||
| Weighted Average Number Of Diluted Shares Outstanding | 319.7M | 250.1M | 116.1M | 44.0M | 37.7M | ||
| Earnings Per Share Basic | $-0.34 | $-0.36 | $-0.96 | $-3.78 | $-4.64 | ||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Outstanding | 285.1M | 204.9M | 187.0M | 63.2M | 38.5M | 37.8M | 10.9M |
| Common Stock Shares Issued | 285.1M | 204.9M | 187.0M | 63.2M | 38.5M | 37.8M | 10.9M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Weighted Average Number Of Share Outstanding Basic And Diluted | 37.7M | 17.7M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.09 | -$0.09 | -$0.08 | -$0.10 | -$0.09 | -$0.10 | -$0.93 | -$0.38 | -$0.28 | -$0.65 | -$0.85 | -$1.32 | -$1.35 | -$1.09 | -$0.87 | -$1.28 | -$1.95 | -$0.50 | -$0.12 | $0.00 |
| Common Stock Shares Authorized | 700.0M | 700.0M | 400.0M | 400.0M | 400.0M | 400.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | |||||
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | |||||
| Weighted Average Number Of Shares Outstanding Basic | 353.3M | 298.0M | 269.3M | 267.8M | 232.8M | 231.2M | 125.7M | 64.2M | 63.3M | 40.9M | 40.1M | 38.2M | 38.0M | 37.5M | ||||||
| Weighted Average Number Of Diluted Shares Outstanding | 353.3M | 298.0M | 269.3M | 267.8M | 232.8M | 231.2M | 125.7M | 64.2M | 63.3M | 40.9M | 40.1M | 38.2M | 38.0M | 37.5M | ||||||
| Earnings Per Share Basic | $-0.09 | $-0.09 | $-0.08 | $-0.10 | $-0.09 | $-0.10 | $-0.93 | $-0.38 | $-0.28 | $-0.65 | $-0.85 | $-1.32 | $-1.35 | $-1.09 | ||||||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Common Stock Shares Outstanding | 273.9M | 272.7M | 205.1M | 204.9M | 201.4M | 187.0M | 187.0M | 64.4M | 63.5M | 41.2M | 41.0M | 38.5M | 38.5M | 38.4M | 37.8M | 37.8M | ||||
| Common Stock Shares Issued | 273.9M | 272.7M | 205.1M | 204.9M | 201.4M | 187.0M | 187.0M | 64.4M | 63.5M | 41.2M | 41.0M | 38.5M | 38.5M | 38.4M | 37.8M | 37.8M | ||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 38.2M | 38.0M | 37.5M | 37.0M | 11.7M | 10.9M | 10.9M | 9.6M | 8.7M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Depreciation | $1.1M | $1.2M | $1.4M | $1.2M | $492.0K | $9.0K | |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $13.3M | $13.1M | $7.9M | $18.3M | $18.6M | $3.4M | |
| Additional Paid In Capital | $958.4M | $677.9M | $587.9M | $402.4M | $331.0M | $312.4M | $980.0K |
| Interest Paid Net | $5.4M | $5.3M | $5.0M | $2.8M | $641.0K | $28.0K | |
| Other Noncash Income Expense | -$296.0K | -$750.0K | -$741.0K | -$906.0K | -$388.0K | ||
| Stock Issued During Period Value Employee Stock Purchase Plan | $159.0K | $89.0K | $68.0K | $253.0K | |||
| Capital Expenditures Incurred But Not Yet Paid | $46.0K | $18.0K | $387.0K | $141.0K | |||
| Change In Fair Value Of Term Loan | $6.2M | $4.6M | $1.5M | ||||
| Investment Income Interest | $9.2M | $6.9M | $3.6M | ||||
| Gain Loss On Fair Value Of Terms Loan Attributable To Instrument Specific Credit Risk | $3.8M | -$4.0M | |||||
| Payment Of Shelf Registration Costs | $387.0K | $358.0K | $360.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Depreciation | $200.0K | $300.0K | $283.0K | $300.0K | $300.0K | $325.0K | $300.0K | $400.0K | $331.0K | $300.0K | $300.0K | $260.0K | $200.0K | $85.0K | $32.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $3.3M | $3.2M | $3.3M | $3.4M | $3.3M | $3.2M | $2.0M | $2.2M | $1.7M | $4.5M | $4.2M | $5.5M | $5.1M | $4.5M | $3.6M | $1.3M | ||||
| Additional Paid In Capital | $903.6M | $900.1M | $681.2M | $674.6M | $664.5M | $591.2M | $511.6M | $406.5M | $404.1M | $357.1M | $352.3M | $336.5M | $325.7M | $320.6M | $316.0M | $310.5M | ||||
| Interest Paid Net | $1.3M | $1.3M | $1.1M | $419.0K | $0.00 | $0.00 | ||||||||||||||
| Other Noncash Income Expense | $5.0K | -$27.0K | -$128.0K | -$194.0K | ||||||||||||||||
| Stock Issued During Period Value Employee Stock Purchase Plan | $84.0K | $75.0K | $63.0K | $26.0K | $18.0K | $50.0K | $253.0K | |||||||||||||
| Capital Expenditures Incurred But Not Yet Paid | $23.0K | $21.0K | $128.0K | $0.00 | $15.0K | |||||||||||||||
| Change In Fair Value Of Term Loan | $1.5M | $1.5M | $1.5M | $1.7M | $1.3M | $1.1M | ||||||||||||||
| Investment Income Interest | $3.2M | $1.9M | $1.3M | $2.1M | $1.4M | $1.7M | $1.1M | |||||||||||||
| Gain Loss On Fair Value Of Terms Loan Attributable To Instrument Specific Credit Risk | -$444.0K | $1.6M | $1.7M | -$4.7M | $2.7M | -$251.0K | ||||||||||||||
| Payment Of Shelf Registration Costs | $47.0K | $387.0K | $151.0K |
Most recent annual filing with the SEC: March 19, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.